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Abstract
The common brushtail possum (Trichosurus vulpecula) is the most significant vertebrate pest in New Zealand, being a major ecological threat to the indigenous biodiversity and an economic threat as a vector for bovine tuberculosis.  Novel and effective strategies to reduce the population of T. vulpecula are needed urgently.  A number of biocontrol agents are currently being assessed and from research to date it is likely that the biocontrol agents will be peptide or protein molecules.  It is not possible to administer such biocontrol agents alone because they would be degraded rapidly in the animal, especially if delivered via the oral route.  Technologies used in the pharmaceutical industry to design efficacious drug delivery systems for humans and animals can be applied to the design of delivery systems for biocontrol agents used in wildlife management, although there are some unique challenges that must be overcome.

Introduction
Overabundant and introduced mammals continue to have unwanted impacts worldwide and there is considerable interest in the development of new and effective methods of control for pest wildlife.  The aim of this review is to provide information for biologists about the technologies used in the formulation and delivery of pharmaceutical compounds that could have application in the biological control of pest wildlife.

In New Zealand, 54 species of mammal have been deliberately introduced including deer, ferrets, stoats, rabbits, rats and hedgehogs (Cowan and Tyndale-Biscoe 1997) and 25 species are currently managed owing to their pest status (Parkes and Murphy 2003).  Although each of these species has had deleterious impacts on the natural flora and fauna, the common brushtail possum is considered to be the major threat to New Zealand’s biodiversity and as such will be the focus of this review.

The common brushtail possum (Trichosurus vulpecula), a marsupial native to Australia, was introduced into New Zealand in the 1850s with the aim of establishing a fur trade (Pracy 1974).  A lack of predators and competitors, and a palatable native flora that lacks chemical defences against browsing herbivores, has enabled the possum population to reach an estimated 70 million with a distribution across more that 90% of New Zealand at densities up to 20 times greater than in their native Australia (Cowan 1990).  The pest status of the brushtail possum in New Zealand has been established because they defoliate native and introduced forests, consume pasture grasses and threatened fauna (e.g. kiwi chicks and land snails) (Brown et al. 1993; Cowan and Moeed 1987). The common brushtail possum is also considered to be the primary wildlife reservoir for bovine tuberculosis (Tb) in New Zealand (Coleman and Caley 2000).

The current lethal methods used to reduce the number of brushtail possums in New Zealand are shooting, trapping and poisoning.  The humaneness of these methods is increasingly coming into question and, whilst effective on a local scale, they are not sufficient to reduce the national population over the long term (Cowan 1996).  Consequently, much research effort has been invested into developing new methods of control that can be added to the existing arsenal.  There are several advantages to using biological control programmes rather than conventional control methods.  The quantities of poisons used in the environment could be reduced and this would also reduce the risk of poisoning non-target species (Cowan 2000).  In addition, after traditional control operations (trapping and poisoning), populations recover more rapidly than can be predicted by birth rates and dispersal alone (Clout and Efford 1984).  Described as the ‘vacuum effect’, neighbouring animals will move into a new area where the local population density has been reduced by control operations (Efford et al. 2000; Ramsey 2005).  Population numbers are able to grow rapidly because of the local abundance of resources.  A strategy that impairs reproduction will have a more sustained effect of reducing the brushtail possum population over the long term, because individuals remain in the population and so are not replaced by immigrants; but they fail to reproduce and so do not contribute to population growth.  It has also been predicted from modelling studies, that bovine Tb would die out in stable, low-density possum populations (Barlow 2000).

The list of desirable characteristics to be incorporated into the design of an ideal biological control agent is daunting.  Ideally it should be:
	Affordable
	Safe
	Not modify animal behaviour
	Target-specific
	Highly potent and induce a permanent effect
	Stable under widely differing environmental conditions

Future control methods
The most publicly acceptable method of eradication for the common brushtail possum by the New Zealand public is biological control and, in particular, fertility control (Fitzgerald et al. 2000).  Biological control relies upon interrupting one or more key biological processes in the target species to cause either death or infertility.  Key reproductive events identified in the common brushtail possum that could be targeted to impair fertility include ovarian function, hormone production, sperm maturation, fertilization and lactation, although targeting the last is deemed unacceptable on ethical grounds (Cowan 1996).  Target systems under investigation include both immune-based and non-immune based (direct) fertility control.  Both present formidable formulation challenges for their delivery, especially if via the oral route.  The first challenge is to deliver the biocontrol agent to the animal in the field.  Delivering biocontrol agents to the brushtail possum via the oral route (in baits) is the most practical choice for delivery because it has a widespread distribution across New Zealand, including remote areas with inaccessible terrain and baits can be distributed aerially and allow broadcast distribution.  The brushtail possum is also a wild animal that is not possible to herd into a confined locality in order to administer a biocontrol agent at close range.

Immunocontraception has received a great deal of attention as a method of fertility control for a number of pest species including foxes (Vulpes vulpes) and rabbits (Oryctolagus cuniculus) in Australia (Seamark 2001) and brushtail possums in New Zealand (Polkinghorne et al. 2005).  With this technique, animals are immunised with key proteins involved with reproduction, such as egg coat (zona pellucida) proteins or sperm proteins.  The body then recognises these self-proteins as foreign and mounts an immune response against them, thus inducing infertility.  That is, they act as a vaccine.  Immunocontraception has been used with success in some populations of feral animals injected with zona pellucida (ZP) antigens.  For example, in wild horses (Equus caballus), greater than 90% infertility that lasted for 1 year has been reported in mares given injections of a porcine ZP vaccine (Turner et al. 2002).  However, when ZP proteins are delivered using recombinant virus vectors that express ZP proteins, no detectable immune response is reported in foxes (Reubel et al. 2005) and rabbits (Mackenzie et al. 2006).  ZP proteins have been characterised for the common brushtail possum (Mate et al. 2003) and Duckworth et al. (1998) reported that in captive brushtail possums, there was a 75% reduction in fertility compared to the control group when females were immunised with whole ZP by subcutaneous injection, although the duration of this infertility is unknown.  Marsupial-specific epitopes of ZP have also been identified (Cui and Duckworth 2005) and are being investigated as a possum-specific vaccine.

There are a number of potential delivery issues with the immunocontraception strategy.  The first of these is how to administer an immunologically effective dose of the agent to free-ranging feral animals in the field.  The most successful studies to date have involved delivery via injection, co-administration of an adjuvant and sometimes more than one vaccination (Cooper and Herbert 2001; Duckworth et al. 1998).  A system that relies upon injecting the animal is not feasible for free-ranging animals and thus alternative delivery systems will be required.  Furthermore, the degree of genetic variation in the immune system between individual animals means that the response to vaccination is likely to vary widely, so a proportion of the population subjected to a standard dose of immunogen may remain fertile (Barlow 1997; Nettles 1997).  For example, Deakin et al. (2005) found that the antibody response by brushtail possums to synthetic peptide hormones was highly variable and these authors questioned the feasibility of immunocontraception as a control method for this species.  The variable immune response has ongoing consequences as only non-responding possums would produce offspring who, most likely would be non-responders.  It has been suggested that the proportion of the possum population that fails to respond to an immunocontraceptive agent would rapidly increase over time (Cooper and Herbert 2001).

In contrast, non-immune-based biocontrol agents (chemical sterilants or hormonal contraceptives) are alternative control agents that would act directly on target cells or tissues and not rely upon an immune response.  Research in this area has been largely focused around luteinizing hormone-releasing hormone (LHRH), owing to its critical role in the regulation of reproductive function.  An example of a hormonal sterilant under investigation is a cytotoxic antiviral protein isolated from the pokeweed plant (Phytolacca decandra).  The protein (pokeweed antiviral protein, PAP) is conjugated to LHRH and then internalised into the gonadotroph cells of the pituitary.  Here, PAP kills the cells that produce luteinizing hormone (LH) and follicle stimulating hormone (FSH) (Eckery et al. 2001).  An alternative approach is to deliver highly potent analogues of LHRH that induce down-regulation of the LHRH receptors (D'Occhio et al. 2000) and thus block the secretion of LH and FSH.  This method requires a controlled-release formulation that delivers the LHRH analogue over a prolonged period, following a single administration.

Direct-acting sterilants or contraceptives are not likely to be influenced by genetic variation between animals, but they can involve special challenges in delivery of the bioactive compound.  For example, those methods described above, require the bioactive compound to be delivered to the pituitary gland.

Species specificity
In New Zealand, chemical control methods (both lethal and fertility control) may be based on exploiting physiological differences between eutherian mammals and the marsupial brushtail possum, to achieve some level of specificity within the biocontrol agent.  It has been demonstrated that some aspects of gastrointestinal (GI) physiology in the brushtail possum are markedly different from those in eutherian mammals (Butt et al. 2002a).  Such differences could potentially be utilised in the design of a species-specific bioactive compound, either by targeting specific differences to disrupt physiological function, or by utilising specific mechanisms for delivery and uptake of the biocontrol agent.  For example, the mechanism that drives the secretion of fluid in the intestine of the common brushtail possum is markedly different from the mechanism identified in placental mammals.  Butt et al. (2002b) have found that the secretion of fluids in the intestine of the brushtail possum is driven by bicarbonate ions, not by chloride ion transport as it is in eutherian mammals.  Research is now focused on how these mechanisms function in the brushtail possum and on the identification of compounds that can irreversibly turn on fluid secretion in the gut.  Hypersecretion in humans causes blood pressure to fall abruptly and the presentation of clinical signs of dehydration, such as lethargy, before coma leading to death.  The effect of such a toxin is yet to be tested in the brushtail possum.  The action of such a toxin would be much more rapid and have fewer clinical signs of distress than the poisons currently used in New Zealand, which include anticoagulants (e.g. brodifacoum), cyanide and the most commonly used compound, 1080 (Littin et al. 2002).

Target specificity can be potentially incorporated at the level of the bioactive compound, but also in the bait if the oral route is chosen for delivery.  This is an important consideration to reduce to risk of affecting non-target species, primarily native birds in New Zealand.  For example, colouring the baits green minimises the attraction of the bait to birds and a cinnamon-scented lure masks the taste of the poison in baits and also repels birds (see Spurr 2000).  Acceptance of the bait is also important to the success of a control programme to ensure that the animals do not become bait shy (O'Connor and Matthews 1999; Ogilvie et al. 2000).  Carrot baits are considered more desirable than cereal baits because they are more palatable to possums and are also more robust in the field (Bowen et al. 1995), also an important consideration when there will be little control over storage conditions for distribution in remote areas.  The infrastructure for producing and distributing poison baits is already well established and the acceptance of baits by the animals is high (Morgan and Hickling 2000), thus there is the potential to incorporate a biocontrol agent within oral baits.

Delivery systems
From research to date, it is highly likely that any biological control agents developed to reduce fertility in the common brushtail possum will be proteins or peptide molecules (Duckworth et al. 2001; Eckery et al. 1999).  Whether the agent is an immunocontraceptive, a chemical sterilant or a toxicant, the challenge is to deliver these biological control agents safely and specifically to a free-ranging, feral animal that has a widespread distribution across the vast majority of the New Zealand landmass, including remote and inaccessible areas.  Delivery systems can be broadly classified as disseminating (transmissible) or non-disseminating, based on their mode of distribution.

	Disseminating delivery systems
The advantage of disseminating delivery systems is their ability to spread the bioactive compound unaided through the target population by means of a vector, which has been administered to only a few animals within that population.  An example of a potential disseminating system for possums under investigation is the naturally occurring, parasitic gut nematode (Parastrongyloides trichosuri) that is brushtail possum-specific (Cowan et al. 2005).  The nematode can rapidly infect large numbers of animals and this has been shown in a field trial in the Kahurangi National Park near Nelson in the South Island of New Zealand (Ralston et al. 2001).  When introduced into a few possums within a parasite-naïve population, the nematode had spread across 400 ha in 52 weeks (over 5000 ha by week 135) and was present at a high prevalence (Ralston et al. 2001).  The assumption is that nematodes that have been genetically modified to contain a gene encoding for a biocontrol agent, would be equally effective in infecting large populations of animals, thus rapidly disseminating the biocontrol agent.

Viruses engineered as vectors to carry genes for immunocontraceptives, or as pathogens, are also under investigation in New Zealand as potential disseminating delivery systems.  Viruses identified from brushtail possums in New Zealand include adenovirus, coronavirus and herpes virus (Rice and Wilks 1996), a possum papillomavirus (PPV) (Perrott et al. 2000) and a retrovirus (Baillie and Wilkins 2001).  Possum adenovirus (PoAdV-1) has been selected as the most promising candidate as a vector because the genomes are easy to manipulate and the viruses are readily transmitted between individuals (Thomson et al. 2002).  A single genotype of PoAdV-1 has been isolated and sequenced from individual possums from different localities in New Zealand (Thomson et al. 2002), although it has not been possible to replicate this virus in cell culture.  The macropod herpes virus (MaHV) causes fatal infections in marsupials such as wallabies and kangaroos in Australia.  The virus can cause mild infections in the brushtail possum (Zheng et al. 2004), however the transmission from infected animals has not been demonstrated and so the usefulness of this delivery system remains to be established.  Another virus infecting brushtail possums is the wobbly possum virus (Mackintosh et al. 1995), but as this invariably causes death, it would not be suitable as a transmission agent.

With all genetically modified organisms and disseminating systems, there is considerable public concern about the inadvertent transfer of these organisms, and the genes they carry, particularly as it would be impossible to withdraw the organism once released.  This is especially so in the case of the common brushtail possum, while a major pest in New Zealand, is a protected and valued endemic animal in Australia.  The potential for inadvertent or illegal transfer to Australia is considered to be high, owing to the frequent exchange of people and goods between the two countries and the precedent of rabbit hemorrhagic disease being illegally brought from Australia to New Zealand (Cooke et al. 2004; Gilna et al. 2005).  There is ongoing debate in the scientific community about what regulatory processes would need to be in place and the management strategies for the implementation of genetic technologies to control overabundant wildlife (Cooke et al. 2004).

	Non-disseminating delivery systems
Whilst having the obvious disadvantage that the biocontrol agent must be administered to each individual animal, non-disseminating delivery systems offer the advantage that the risks of uncontrolled spread are removed and that the biocontrol agent can be withdrawn if necessary.  There is a wide range of potential non-disseminating delivery systems including genetically modified plants, such as carrots and potatoes, that express an immunocontraceptive vaccine within the genome of the transgenic plant (Smith et al. 1997).  The plant material can then be fed directly to the animal or incorporated into baits.  Carrots are already used as baits in poison operations for possums and this root plant material has the advantage that it is robust in the environment (Polkinghorne et al. 2005).

Another example of a non-disseminating system is bacterial ghosts.  Bacterial ghosts are empty envelopes of cell membrane from dead Gram-negative bacterial cells that retain the surface antigens of the living cell (Mayr et al. 2005).  Recombinant proteins and antigens can be loaded onto the inner or outer cell membranes, or within the periplasmic space or in the lumen of the cytoplasmic space of the bacterial ghosts (Mayr et al. 2005).  The ghosts are taken up by the dendritic cells of the immune system of the target animal, processed and the recombinant proteins expressed within the host (Jalava et al. 2002).  An advantage of bacterial ghosts as an antigen carrier is that the ghosts retain their immunostimulatory membrane structure.  However, in studies to date, the immune response after oral administration of ghosts containing ZP antigen to the common brushtail possum has been low (Duckworth et al. 2001), which may be due to degradation of the ghosts in the gastrointestinal tract.  Their stability following oral ingestion is an area of current investigation (J. A. Duckworth pers. comm.).

Virus-like particles (VLPs) are another non-disseminating delivery system that targets the immune system.  VLPs are composed of structural proteins that are able to self-assemble into hollow particulates and they have been investigated for application in delivery of DNA and therapeutic proteins to treat human diseases (Pattenden et al. 2005).  VLPs are non-infectious, but able to stimulate the immune system because they mimic the structure of viruses (Jiang et al. 1999).  VLPs from more than 30 viruses are being developed for use in both humans and animals (Noad and Roy 2003).  Although there is evidence that these delivery systems are effective and safe, they are more costly to attenuated vaccines because higher doses of antigen are needed compared to attenuated vaccines (Noad and Roy 2003).

Routes of delivery
The preferred route for the administration of biologically active compounds, in terms of maintaining potency and maximising concentrations in the circulation, is via injection (either intravenous, subcutaneous or intramuscular).  However, the distribution of pest species over large land areas and the wild nature of pests, means that injections are not practical.  The nasal route offers some advantages for the delivery of peptide and protein biocontrol agents for a number of reasons: this route avoids first-pass metabolism in the liver; enzyme degradation is much lower than in the intestine; and the mucosal surface is highly vascular and has a large surface area (Illum 2002).  However, it would be necessary to administer such a nasal formulation from a mechanical device designed to deliver a spray to animals in the field.  A spray device would be technically very difficult to achieve and to maintain in the field.  Furthermore, a study by McLeod et al. (1998) on the common brushtail possum reported low systemic uptake of a model peptide hormone, LHRH, following nasal administration.

Delivery using an oral bait is likely to be the easiest, safest and most convenient method for delivery in the field to widely dispersed wild animals such as the common brushtail possum (Rodger 1999).  The oral route is used primarily to achieve a systemic effect following absorption of the bioactive from the GI tract.  However, before compounds can be absorbed from the GI tract, the formulation must be able to withstand the acidic environment of the stomach, be emptied from the stomach within an appropriate time to limit degradation and reach the site of absorption.

Formulation strategies to enhance oral delivery of peptides
Peptides and proteins have poor intrinsic permeability across membranes owing to their hydrophilicity, electrical charge and structural conformation (Yang et al. 2002), which results in a bioavailability (the fraction of an administered dose that reaches the systemic circulation) of typically 1–2%.  In addition to the physical barrier of the epithelium lining the GI tract, there is also a chemical barrier, where compounds may be exposed to enzymatic degradation by the secretions of the GI tract (Mahato et al. 2003).  These barriers to the oral delivery of proteins and peptides can, at least in part, be overcome by using formulation strategies that protect the bioactive compound and to facilitate absorption across the intestinal mucosa.

	Chemical modification
One technique that can be used to enhance the stability and uptake of peptides in the body is to attach a lipid portion to the peptide.  Such chemical modification of the bioactive compound by lipidification results in a higher affinity with the phospholipid cell membrane, which enhances passive transport across the intestinal membrane (Toth et al. 1999).  In addition, the stability of the peptide is improved by the attachment of a lipid group, because enzyme recognition of cleavage sites is interrupted by the presence of the lipid side chain (Toth et al. 1999).  Lipidification of the polypeptide salmon calcitonin has been shown to increase its retention in the plasma of rats when injected subcutaneously (Wang et al. 2003) and thus  increasing the time available for uptake into target tissue(s).  Similarly, after oral administration to rats, radiolabelled LHRH–lipid conjugates were absorbed into the systemic circulation and retained in plasma for up to 10 h (Flinn et al. 1996).

	Penetration enhancers and enzyme inhibitors
Co-formulation with penetration enhancers (bile salts or detergents), which disrupt the tight junctions that bind epithelial cells to their neighbouring cells, can enhance paracellular absorption of bioactive compounds (Aungst 2000).  The transcellular pathway can also be disrupted by penetration enhancers and lead to increased transport of peptides and proteins in the intestine.  Examples of the types of penetration enhancers used include chelating agents that bind Ca2+ in the tight junctions (Noach et al. 1993) and surfactants and bile salts that disrupt the cell membrane integrity (Schep et al. 1997) (Table 1).  McLeod et al. (2005) have demonstrated in the common brushtail possum that, when co-administered with sodium deoxycholate (SDA), the intestinal permeability of the reference compounds fluorescein and LHRH increased 33-fold and 63-fold respectively.

[Approximate position of Table 1]

Enzyme inhibitors (Table 1) can also be used as excipients (those ingredients other than the bioactive compound included in a formulation) to reduce the degradation of bioactive peptides and proteins by hydrolysis in the GI tract.  In the specific case of the common brushtail possum, soybean trypsin-chymotrypsin inhibitor, SDA, carbopol and bacitracin all significantly inhibited the degradation of LHRH and bovine serum albumin (BSA) in vitro in the presence of enzymes from the GI tract (Wen et al. 2002a).

	Particulate delivery systems
A particulate delivery system that incorporates the bioactive compound is an attractive formulation option for protecting the bioactive compound from enzymatic degradation in the body and for facilitating its subsequent uptake at the target site.  For example, liposomes are a versatile colloidal delivery system because both their size (20 nm – 2 m) and composition (single or multiple bilayers) can be manipulated.  In addition, they have both lipophilic and hydrophilic domains within their structure that can be utilised to carry a range of drugs and vaccines (Sihorkar and Vyas 2001).  Liposomes have been successfully used in mice to deliver the protein insulin via the lungs leading to a reduction in blood glucose levels (Huang and Wang 2006).  Liposomes may have some potential to be used for the oral delivery of peptides and proteins, although in vivo results to date have been variable (Rogers and Anderson 1998) because liposomes are unstable in the lower GI tract (Faas et al. 2001).

Another type of particulate delivery system that can protect the bioactive compound in vivo is microparticles (microspheres or microcapsules).  In the size range between 1 m and 1 mm, microparticles are spherical drug carriers made of selected polymers that have low toxicity and high biocompatibility (Kissel and Koneberg 1996).  The polymers used most extensively to prepare microparticles are poly(lactic acid) (PLA) (Vila et al. 2002) and poly(lactic-co-glycolic acid) (PLGA) (Damgé et al. 1996).  Recently there has been considerable research into the use of PLGA microparticles for the delivery of vaccine antigens and DNA, because they are able to act as adjuvants and elicit a cytotoxic response in vivo (Jiang et al. 2005), an essential quality when the immune system is the target.  Despite the advantages of microparticles, the stability of proteins once entrapped within them can be low (Schwendeman 2002).

Nanoparticles are a promising and versatile delivery system suitable for the delivery of a range of therapeutic agents ranging from small molecular weight drugs to macromolecules (proteins and peptides) and DNA (Panyam and Labhasetwar 2003; Tiyaboonchai et al. 2003).  Nanoparticles are polymeric, spherical structures in the size range of 10–1000 nm and have the advantage that they are stable in biological fluids, can protect therapeutic agents from enzymatic degradation and can provide controlled drug release profiles owing to their polymeric nature (Damgé et al. 1997; Moghimi et al. 2001).  Depending on the method of nanoparticle preparation, therapeutic agents can be dissolved, encapsulated or adsorbed to the nanoparticle.  There are two different types of nanoparticles recognised in the literature (Fig. 1): nanocapsules that contain the drug within an internal cavity surrounded by a polymer wall and nanospheres that are solid matrix systems with the drug dispersed throughout the matrix (Soppimath et al. 2001).  The core of the nanoparticle can be an oily compartment for the encapsulation of lipophilic drugs (Cournarie et al. 2004; Fallouh et al. 1986) or an aqueous core for the incorporation of hydrophilic drugs (Watnasirichaikul et al. 2002a).

[Approximate position of Fig. 1]

Particulates in this sub-micron size range have been shown to move across the gut epithelium and enter the systemic circulation (Aboubakar et al. 2000; Damgé et al. 2000; Kreuter 1996), and they can be taken up by epithelial cells (Florence et al. 1995).  For example, in the rat, uptake of nanoparticles from the intestine was up to 250 times greater for 100 nm sized particles compared to 1 m particles (Desai et al. 1996).  The particle size is a property that can be controlled during the preparation of nanoparticles (Damgé et al. 1996; Vila et al. 2004).  Watnasirichaikul et al. (2002b) have demonstrated the effectiveness of poly(ethyl cyanoacrylate) (PECA) nanoparticles containing insulin to reduce blood glucose levels in diabetic rats.

	Targeting the colon
There are advantages to delivering bioactive compounds to the colon compared to other regions of the gut including a near-neutral pH, lower proteolytic activity than in upper regions of the GI tract and a long transit time increasing opportunities for uptake (Sinha and Kumria 2003).  For the common brushtail possum, Wen et al. (2002b) have demonstrated that the proteolytic activity of enzymes from both the lumen and mucosa of the hindgut were 100–1000-fold less aggressive towards a model peptide (LHRH) and protein (BSA) compared to those in the small intestine.  There are a number of strategies that have been suggested to achieve site-specific delivery of bioactives to the colon region of the gastrointestinal tract (Friend 2005).  Many of these rely on the physiological differences between this region and the small intestine.  For example, there is a gradual change in pH throughout the GI tract that could potentially be used to trigger the disintegration of polymer-coated systems.  However, Ashford et al. (1994) have shown that there is great variability in the site of release when using pH as the trigger mechanism with polymethacrylate coated tablets in vivo.

Surrounding a particulate formulation with an enteric coating can protect the delivery system from the acidic environment in the stomach after oral ingestion.  Pectin, ethylcellulose, guar gum and chitosan are examples of the polymers that have been used for colon-targeted delivery (Macleod et al. 1999; Sinha and Kumria 2001; Wakerly et al. 1996).  Contained in the colon is an abundant and diverse microflora that functions to ferment fibre with hydrolytic enzymes (Watts and Illum 1997).  The enzymes secreted by the microflora in the colon can also be utilised to degrade the polymer and thus to release the bioactive compound.  Bacteria-mediated degradation is a promising area for targeted delivery because of the abrupt increase in microflora between the small intestine and the colon (Sinha and Kumria 2003).

The use of pro-drugs is another strategy that has been used to target the delivery of drugs to the colon.  A pro-drug is a polymer–drug conjugate and is defined as an inactive derivative of a drug that requires enzymatic transformation to release the active drug (Reddy et al. 1999).  To target the colon, the system relies on the enzymes produced by colon-specific bacteria.  The most commonly used and most extensively studied pro-drugs are those with an azo-bond between the active molecule and the inactive moiety (Sinha and Kumria 2003).  An example is the pro-drug sulphasalazine containing the active drug mesalamine, used for the treatment of irritable bowl syndrome in humans (Friend 2005).

In order to target the colon as a site for drug release following oral administration, it is essential to have knowledge of gastrointestinal transit times and of the factors that influence transit through the GI tract.  These have been extensively characterised in humans (Wilding et al. 2001), where total gastrointestinal transit times can be influenced by factors such as posture, physical activity and stress level of the individual (Coupe et al. 1992), and are determined largely by gastric emptying (Smart and Kellaway 1989).  The gastrointestinal transit of oral formulations has been investigated in the brushtail possum (McDowell et al. 2005).  To target the hindgut for oral delivery of protein and peptide biocontrol agents, a formulation would need to protect the bioactive compound and prevent release for approximately 12 h.  Gastrointestinal transit was shown to be independent of body mass, gender and time of day that the animal receives the dose (McDowell et al. 2005).  This is valuable information when considering remote delivery of oral baits to brushtail possums in the field where it is not possible to control when the animal consumes the bait.

Delivery system considerations
A key issue when considering broad-scale distribution of a delivery system containing a biocontrol agent is the potential affect on non-target species.  As discussed previously, specificity of the biocontrol agent for common brushtail possums in New Zealand is being investigated by targeting physiological characteristics that are unique to marsupials.  The disseminating delivery system that has the most potential for specificity is the nematode vector, Parastrongyloides trichosuri.  For the non-disseminating delivery systems (baits), the knowledge obtained through poisoning control operations could be adopted (Morgan and Hickling 2000).

Assessment of delivery systems in vivo
Any potential delivery system must be evaluated in vivo in the target species.  Achieving appropriate physiological concentrations of the bioactive compound in the plasma of the animal is the first critical part of successfully achieving the desired response of a biological control agent (e.g. a reduction in fertility).  The development of formulation strategies for oral delivery of peptides and proteins to be applied to a marsupial species, the common brushtail possum, is an especially difficult challenge, because there are gaps in our knowledge of basic physiology of the brushtail possum and very little information on formulations for use with marsupials is available.  McLeod et al. (2005) have investigated the pharmacokinetics following intestinal absorption of the model compounds fluorescein and LHRH in the common brushtail possum.  These authors found the plasma concentration of fluorescein increased from 0.3  0.01 g/mL to 7.8  1.64 g/mL with the addition of SDA as a permeation enhancer and LHRH rose from 0.1  0.02 ng/mL to 6.3  0.45 ng/mL with addition of the enhancer.

Until specific biocontrol compound(s) are identified, research on the development of pharmaceutical delivery systems for the common brushtail possum is being conducted using ‘model’ peptides and proteins.  Once a potential bioactive candidate has been identified, it will be necessary to understand the physiochemical properties of the active compound (e.g. stability) in addition to the biological factors that influence absorption and degradation.

The effectiveness of biocontrol agents will also need to be evaluated in the target species at the population level.  When used in the situation of managing pest species, population modelling can be used to predict the outcome of different control regimes, estimate the amount of control effort that needs to be applied and estimate the success of control operations on the target population (Barlow 2000).  In New Zealand, population modelling has been used to predict brushtail possum population dynamics in response to harvesting for their fur (Clout and Barlow 1982).  More recently there has been an emphasis on modelling Mycobacterium bovis infection, the cause of bovine Tb, and the role that the brushtail possum population has in transmitting this disease (Arthur et al. 2004; Caley and Ramsey 2001).  Through such modelling studies, useful information has been obtained about the population dynamics of the brushtail possum in different habitats in New Zealand, such as density, survival and distribution (Efford 2000).

Stability of formulations in the field
Preserving viability of the bioactive compound during manufacture, storage and administration is of vital importance.  Hydrolysis and oxidation are the most common forms of chemical degradation for bioactive compounds (Florence and Attwood 1998), although the specific type of degradation pathway will depend on the chemical nature of the bioactive compound in question.

An aspect of delivery systems important to wildlife applications, not usually considered in the pharmaceutical setting, is the stability of formulations under extremes of environmental conditions, as would be encountered in the field.  Formulations developed for field use for control of the common brushtail possum in New Zealand will be exposed to a range of temperatures including wide day/night fluctuations, extremes of humidity, freeze/thaw cycles, ultra-violet light and rainfall, and fungal and microbial contamination.  Consequently, the delivery system or dosage form can undergo chemical, physical and microbial degradation.  Thus, the stability of the dosage form under environmental conditions will need to be assessed and the formulation must incorporate features that will protect the bioactive compound without compromising potency or delivery to the targeted region of the gastrointestinal tract.

Conclusion
The development of biological control methods for vertebrate pest wildlife requires innovative approaches.  For a biological control program to be successful, it must be underpinned by the ability to effectively administer the control agent(s) to the target population.  Approaches used in the pharmaceutical industry can potentially be applied drug delivery to wildlife.  To apply the techniques developed in the pharmaceutical industry to management of pest species, it is necessary to characterise relevant aspects of the biology and physiology of the target species and to develop in vivo methods to assess the effectiveness of delivery systems.  Any future biological control strategy should be used in combination with traditional control methods in an integrated management system to achieve a sustainable reduction in the population.
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Table 1.  Examples of permeation enhancers and enzyme inhibitors used to improve the oral delivery of peptides and proteins in mammals (Mahato et al. 2003).

	Group of compounds	Example compound
Permeation enhancers		Chelating agents	Ethylene diamine tetra-acetic acid (EDTA)
		Surfactants	Sodium dodecyl sulphate (SDS)
		Bile salts	Sodium deoxycholate (SDA)
		Fatty acids	Lauric acid
		Mucoadhesive polymers	Chitosan
Enzyme inhibitors		Chelating agents	Ethylene diamine tetra-acetic acid (EDTA)
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